News

VIVA Pharm, one of the leading pharmaceutical companies in Kazakhstan, successfully completed an important Antimicrobial Resistance (AMR) program, conducted in collaboration with the British Society for the Chemotherapy of Infectious Diseases (BSAC). This program, supported by the European Bank for Reconstruction and Development (EBRD) and the Government of Japan, was aimed at managing AMR risks in the pharmaceutical sector of Kazakhstan, as well as ensuring sustainable and equitable access to antibiotics in the country.
As part of the program, a thorough audit of VIVA Pharm's practices was conducted, including an assessment of the standards for the production, storage and destruction of medicinal products. Particular attention was paid to the antimicrobial resistance management (AMS) procedures and environmental protection. A visit to the company's production facilities in Almaty confirmed the high quality of the processes and compliance with GMP standards.
The AMR and AMS program is key to the development of VIVA Pharm and demonstrates the company's commitment to solving one of the most important global health problems - antibiotic resistance.
Key findings of the program include:
• High quality of products and processes.
• Development of the AMS strategy.
• Interaction with suppliers.
• Pharmacy audit.